Dosage of Syr Montair LC Kid (Montelukast and Levocetirizine) in Children Based on Age and Weight
For children aged 2-5 years, the recommended dose of montelukast is 4 mg once daily, while for children 6-14 years, the dose is 5 mg once daily. 1, 2
Age-Based Dosing Recommendations
- 1-5 years of age: 4 mg montelukast once daily (usually as a chewable tablet or granules) 3, 1
- 6-14 years of age: 5 mg montelukast once daily (usually as a chewable tablet) 3, 1
- ≥15 years and adults: 10 mg montelukast once daily (film-coated tablet) 1
Formulation Considerations
- The 4 mg chewable tablet or granule formulation is FDA-approved for children 2-5 years of age 3, 2
- The 5 mg chewable tablet is FDA-approved for children 6-14 years of age 3, 2
- For children 1-2 years, the 4 mg oral granule formulation is recommended 1
Pharmacokinetic Considerations
- The 4 mg dose in 2-5 year olds provides similar systemic exposure to the 10 mg adult dose 4
- The 5 mg dose in 6-14 year olds was specifically selected to provide comparable plasma concentration-time curve (AUC) to the adult 10 mg dose 5, 6
- Montelukast has a half-life of 2.7-5.5 hours in healthy young adults 1
- The drug is administered once daily, typically in the evening 2
Levocetirizine Component
- While specific guidelines for levocetirizine in Montair LC are limited in the provided evidence, levocetirizine is typically dosed at:
- 1.25 mg once daily for children 6 months to 5 years
- 2.5 mg once daily for children 6-11 years
- 5 mg once daily for children ≥12 years and adults 3
Clinical Considerations
- Montelukast is a leukotriene receptor antagonist that modifies the action of leukotrienes, which are potent bronchoconstrictors 2
- Onset of action begins within one hour of administration 2
- The medication should be administered once daily, preferably in the evening 2
- Patient satisfaction and compliance is generally better with montelukast than inhaled medications due to its oral, once-daily administration 2, 7
Safety Considerations
- Montelukast is generally well-tolerated in children with adverse event profiles similar to placebo 7
- No dosage adjustment is required for patients with mild-to-moderate hepatic insufficiency 1
- No dosage adjustment is required for patients with renal insufficiency 1
- Monitor for rare adverse effects including neuropsychiatric events 1
Clinical Efficacy
- In children 2-5 years old, montelukast treatment results in significant improvements in symptom scores and reduction in as-needed beta2-agonist usage 7
- In children 6-14 years old, montelukast significantly improves FEV1 and reduces exacerbation rates 7
Remember that Syr Montair LC Kid contains both montelukast and levocetirizine, so proper dosing of both components is essential for optimal therapeutic effect while minimizing potential adverse effects.